RedHill Biopharma Ltd.

RDHL

US7574682024

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.4581 ^USD	-0.04%		-1.02%	-68.62%

May. 06	Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib	MT
May. 06	RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035	CI

RedHill Biopharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023

June 12, 2023 at 08:00 am EDT

RedHill Biopharma Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 3.6 million compared to USD 13.1 million a year ago. Net income was USD 50.24 million compared to net loss of USD 20.53 million a year ago.

Basic loss per share from continuing operations was USD 20 compared to basic earnings per share from continuing operations of USD 16 a year ago.

Latest news about RedHill Biopharma Ltd.

Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib	May. 06	MT
RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035	May. 06	CI
RedHill Biopharma Ltd Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study	Apr. 24	CI
RedHill Biopharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
RedHill Biopharma Ltd. cancelled the transaction announced on March 8, 2023	Mar. 27	CI
Redhill Biopharma Says Talicia Gets New US Patent to Treat Helicobacter Pylori Infection	Mar. 11	MT
U.S. government Selects RedHill Biopharma Ltd.'s Opaganib for Evaluation by BARDA and NIH Countermeasures Programs	Mar. 05	CI
Redhill Biopharma Ltd. Announces New Publication of Data from Multiple Experiments in the International Journal of Molecular Sciences	Feb. 20	CI
Redhill Biopharma Closes $8 Million Registered Direct Offering of American Depositary Shares	Jan. 26	MT
RedHill Biopharma to Seek Acquisitions	Jan. 26	CI
ADRs Close Higher; Addex Therapeutics Climbs 21%	Jan. 25	DJ
Top Midday Decliners	Jan. 25	MT
Redhill Biopharma Launches $8 Million Offering of American Depositary Shares; Stock Falls	Jan. 25	MT
ADRs Close Higher, Evaxion Biotech A/S Climbs 113.4%	Jan. 24	DJ
Sector Update: Health Care Stocks Retreat Late Afternoon	Dec. 20	MT
Sector Update: Health Care Stocks Mixed in Wednesday Afternoon Trading	Dec. 20	MT
Redhill Says Opaganib, RHB-107 Combinations With Remdesivir Show 'Robust Synergistic Effect' Against Ebola; Shares Rise	Dec. 20	MT
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola	Dec. 20	CI
ADRs End Lower, Redhill Biopharma Ltd. Declines 22.6%	Dec. 06	DJ
U.S.-LISTED SHARES OF REDHILL BIOPHARMA RISE 2.4% ON ADDITIONAL…	Dec. 04	RE
Redhill Biopharma Says it Received $4.8 Million in Additional Funds for Study of Early COVID-19 Treatment	Dec. 04	MT
ADRs Close Higher; Akso Health Group Climbs 24%	Dec. 01	DJ
ADRs Close Higher; Incannex Healthcare Inc. Climbs 723.7%	Nov. 30	DJ
Top Premarket Decliners	Nov. 30	MT
ADRs End Flat; Sunlands Technology Group Climbs 31%	Nov. 29	DJ

Chart RedHill Biopharma Ltd.

Duration

Period

More charts

Company Profile

RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelersâ diarrhea. RedHillâs clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Sector

Pharmaceuticals

Calendar

2024-08-14 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
REDHILL BIOPHARMA LTD.	-68.62%	14.6M
CSL LIMITED	-2.29%	89.87B
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	37.57B
BIOGEN INC.	-13.07%	32.75B
UCB	+63.05%	26.47B
BIOMARIN PHARMACEUTICAL INC.	-22.14%	14.25B
INCYTE CORPORATION	-7.96%	12.99B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.33%	11.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.33%	10.84B
SWEDISH ORPHAN BIOVITRUM AB	+5.77%	9.11B

Biopharmaceuticals